What to Trust, PSA or [68Ga]Ga-PSMA-11: Learn from Experience
Rita Viglialoro,1,2,* Enrica Esposito,1,2,* Roberta Zanca,1,2 Marco Gessi,3 Tommaso Depalo,1,2 Gayane Aghakhanyan,1,2 Francesco Bartoli,1,2 Martina Sollini,4,5 Paola Anna Erba1,2,6 1Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medici...
Main Authors: | Viglialoro R, Esposito E, Zanca R, Gessi M, Depalo T, Aghakhanyan G, Bartoli F, Sollini M, Erba PA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-08-01
|
Series: | Research and Reports in Urology |
Subjects: | |
Online Access: | https://www.dovepress.com/what-to-trust-psa-or-68gaga-psma-11-learn-from-experience-peer-reviewed-fulltext-article-RRU |
Similar Items
-
Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11
by: Nicole N. Waterhouse, et al.
Published: (2020-02-01) -
Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [<sup>68</sup>Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
by: Jing Zhao, et al.
Published: (2020-11-01) -
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
by: Vikas Prasad, et al.
Published: (2021-03-01) -
Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer
by: Jing Zhao, et al.
Published: (2020-12-01) -
Optimization of injected 68Ga-PSMA activity based on list-mode phantom data and clinical validation
by: J. Wielaard, et al.
Published: (2020-04-01)